Wall Street analysts are telling retail investors to buy UroGen Pharma while short sellers bet the stock comes crashing down — and the company still hasn't made a dime of profit.
The setup is as old as the market itself: institutional voices pump a surging stock, working Americans pile in, and the shorts walk away with the winnings. UroGen Pharma has surged nearly 180% over the past year and just hit an all-time high of $41.36, according to Barchart. Seven Wall Street analysts rate it a "Strong Buy" with price targets up to $45. Meanwhile, short interest sits at 12.76% of the float with 9.42 days to cover — a meaningful bet against the company by traders willing to put real money on the line.
The bull case rests on projections, not profits. Revenue is projected to grow 147.80% this year and 56.03% next year, with earnings estimated to rise 75.08% and 263.68% in those same periods, Barchart reported. But UroGen has posted five straight years of revenue growth and still hasn't broken even. The company is a clinical-stage biopharmaceutical firm with a $1.94 billion market cap and zero profits to show for it.
Not every analyst is drinking the Kool-Aid. Value Line rates the stock "Average." CFRA's MarketScope rates it a "Hold." Morningstar says it's fairly valued. Two of the nine analysts tracked by Barchart say "Hold" rather than buy. The widest price target spread — $18 to $45 — tells you everything about how much conviction those "Strong Buy" ratings actually carry.
Barchart framed the story around technical momentum and earnings projections, burying the short interest and the company's unprofitability deep in the piece. The technical indicators — a 100% "Buy" signal, an RSI of 71.88 approaching overbought territory, a 60-month beta of 1.56 — paint the picture of a stock running hot. Barchart even noted in a disclosure that its "Chart of the Day" stocks "are not intended to be buy recommendations as these stocks are extremely volatile and speculative." That disclaimer came after paragraphs of bullish data.
The pattern is familiar. Yahoo Finance reported this week that Netflix beat earnings estimates and still saw its stock tank over 10% after revenue fell short of Wall Street expectations and guidance disappointed. Bloomberg Intelligence senior media analyst Geetha Ranganathan told Yahoo Finance: "There is definitely some kind of slowdown, and I'm not necessarily sure management has articulated what they can do to reinvigorate the business here." Netflix shares are down 40% over the past 12 months despite being a profitable, established company — a stark contrast to UroGen's 180% gain on zero earnings.
Wall Street sets the expectations, misses them, and retail pays the price. Netflix "beat" on earnings and got punished. UroGen has never earned a profit and gets seven "Strong Buys." The shorts aren't betting on UroGen's fundamentals — they're betting that the retail crowd will eventually run out of momentum.
The question isn't whether UroGen's stock keeps climbing. It's who gets out first when it stops — and it won't be the institutions.
